SNDX Q3 2019 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$379,000+0.0% YoY

Gross Profit

$379,000100.0% margin

Operating Income

-$13M-3469.4% margin

Net Income

-$13M-3385.0% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$76M

Total Liabilities

$32M

Stockholders' Equity

$44M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379,000	$379,000	+0.0%
Gross Profit	$379,000	$379,000	+0.0%
Operating Income	-$13M	-$18M	+26.3%
Net Income	-$13M	-$17M	+26.0%